{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:32:13Z","timestamp":1790742733677,"version":"4.1.0"},"reference-count":36,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Few studies have compared the incidence of infections occurring \u22652 years after hematopoietic cell transplant (HCT) with other cancer patients and the general population. In this study, \u22652-year HCT survivors who were Washington residents treated from 1992 through 2009 (n = 1792; median age, 46 years; 52% allogeneic; 90% hematologic malignancies) were matched to individuals from the state cancer registry (n = 5455, non-HCT) and driver\u2019s license files (n = 16\u2009340; Department of Licensing [DOL]). Based on hospital and death registry codes, incidence rate ratios (IRRs; 95% confidence interval [CI]) of infections by organism type and organ system were estimated using Poisson regression. With 7-year median follow-up, the incidence rate (per 1000 person-years) of all infections was 65.4 for HCT survivors vs 39.6 for the non-HCT group (IRR, 1.6; 95% CI, 1.3-1.9) and 7.2 for DOL (IRR, 10.0; 95% CI, 8.3-12.1). Bacterial and fungal infections were each 70% more common in HCT vs non-HCT cancer survivors (IRR, 1.7; P &amp;lt; .01), whereas the risk for viral infection was lower (IRR, 1.4; P = .07). Among potentially vaccine-preventable organisms, the IRR was 3.0 (95% CI, 2.1-4.3) vs the non-HCT group. Although the incidences of all infections decreased with time, the relative risk in almost all categories remained significantly increased in \u22655-year HCT survivors vs other groups. Risk factors for late infection included history of relapse and for some infections, history of chronic graft-versus-host disease. Providers caring for HCT survivors should maintain vigilance for infections and ensure adherence to antimicrobial prophylaxis and vaccination guidelines.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001470","type":"journal-article","created":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:37:57Z","timestamp":1585568277000},"page":"1232-1241","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Late infectious complications in hematopoietic cell transplantation survivors: a population-based study"],"prefix":"10.1182","volume":"4","author":[{"given":"Aimee M.","family":"Foord","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle Children\u2019s Hospital, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara L.","family":"Cushing-Haugen","sequence":"first","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Boeckh","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division and"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5021-0714","authenticated-orcid":false,"given":"Paul A.","family":"Carpenter","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle Children\u2019s Hospital, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary E. D.","family":"Flowers","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2600-6390","authenticated-orcid":false,"given":"Stephanie J.","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7405-0906","authenticated-orcid":false,"given":"Wendy M.","family":"Leisenring","sequence":"first","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Mueller","sequence":"first","affiliation":[{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Department of Epidemiology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle, WA;"},{"name":"Vaccine and Infectious Disease Division and"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7712-961X","authenticated-orcid":false,"given":"Eric J.","family":"Chow","sequence":"first","affiliation":[{"name":"Department of Pediatrics, University of Washington, Seattle Children\u2019s Hospital, Seattle, WA;"},{"name":"Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA;"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,3,30]]},"reference":[{"issue":"10","key":"2020033011375257700_B1","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.bbmt.2013.07.020","article-title":"Prevalence of hematopoietic cell transplant survivors in the United States","volume":"19","author":"Majhail","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2020033011375257700_B2","unstructured":"D'Souza\n              A\n            , FrethamC. Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT). CIBMTR Summary Slides, 2019. https:\/\/www.cibmtr.org. Accessed 10 February 2020."},{"issue":"6","key":"2020033011375257700_B3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bbmt.2016.10.001","article-title":"National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report","volume":"23","author":"Gea-Banacloche","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020033011375257700_B4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.bbmt.2018.09.004","article-title":"Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival","volume":"25","author":"Alousi","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020033011375257700_B5","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2009.25.6693","article-title":"Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation","volume":"28","author":"Martin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020033011375257700_B6","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41409-017-0076-2","article-title":"Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation: a single center analysis of 389 consecutive patients","volume":"53","author":"Solh","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"2020033011375257700_B7","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood.2018874115","article-title":"Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation","volume":"133","author":"Baker","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020033011375257700_B8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.bbmt.2018.09.031","article-title":"Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation","volume":"25","author":"Norkin","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2020033011375257700_B9","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.bbmt.2007.07.007","article-title":"Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor","volume":"13","author":"Robin","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2020033011375257700_B10","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2016.68.8457","article-title":"Morbidity and Mortality Differences Between Hematopoietic Cell Transplantation Survivors and Other Cancer Survivors","volume":"35","author":"Chow","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020033011375257700_B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbmt.2011.12.519","article-title":"Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation","volume":"18","author":"Majhail","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2020033011375257700_B12","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.bbmt.2016.01.023","article-title":"Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children\u2019s Oncology Group Report","volume":"22","author":"Chow","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020033011375257700_B13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"11","key":"2020033011375257700_B14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/sim.4780121103","article-title":"Robust inference for multivariate survival data","volume":"12","author":"Segal","year":"1993","journal-title":"Stat Med"},{"key":"2020033011375257700_B15","author":"Therneau","year":"2000"},{"issue":"10","key":"2020033011375257700_B16","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1182\/blood.V86.10.3979.bloodjournal86103979","article-title":"Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients","volume":"86","author":"Ochs","year":"1995","journal-title":"Blood"},{"issue":"3","key":"2020033011375257700_B17","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1182\/blood.V60.3.714.714","article-title":"Analysis of late infections after human bone marrow transplantation: role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease","volume":"60","author":"Atkinson","year":"1982","journal-title":"Blood"},{"key":"2020033011375257700_B22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canep.2018.05.001","article-title":"A prospective study of cancer survivors and risk of sepsis within the REGARDS cohort","volume":"55","author":"Moore","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"16","key":"2020033011375257700_B23","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1002\/cncr.28763","article-title":"Infections among long-term survivors of childhood and adolescent cancer: a report from the Childhood Cancer Survivor Study","volume":"120","author":"Perkins","year":"2014","journal-title":"Cancer"},{"issue":"11","key":"2020033011375257700_B24","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1705856","article-title":"Risk factors for fatal infectious complications developing late after allogeneic stem cell transplantation","volume":"40","author":"Bjorklund","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"8","key":"2020033011375257700_B25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2009.263","article-title":"Vaccination of hematopoietic cell transplant recipients","volume":"44","author":"Ljungman","year":"2009","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"2020033011375257700_B26","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1093\/cid\/cit684","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2020033011375257700_B27","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in Biol Blood Marrow Transplant. 2010 16(2):294]","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6A","key":"2020033011375257700_B28","first-page":"7","article-title":"Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: recommendations of CDC, the Infectious Diseases Society of America, and the American Society of Blood and Marrow Transplantation","volume":"6","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"2020033011375257700_B29","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S1473-3099(18)30600-5","article-title":"Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Cordonnier","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"23","key":"2020033011375257700_B30","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2015-12-550475","article-title":"How I vaccinate blood and marrow transplant recipients","volume":"127","author":"Carpenter","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020033011375257700_B31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1182\/blood-2009-03-208983","article-title":"Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD","volume":"114","author":"Vigorito","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2020033011375257700_B32","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of Immunosuppressive Treatments in Patients with Chronic Graft-versus-Host Disease","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"2020033011375257700_B19","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bbmt.2015.09.013","article-title":"Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors","volume":"22","author":"Young","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2020033011375257700_B33","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/acr.21959","article-title":"Systematic review of validation studies of the use of administrative data to identify serious infections","volume":"65","author":"Barber","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2020033011375257700_B34","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annepidem.2013.02.005","article-title":"Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data","volume":"23","author":"Drahos","year":"2013","journal-title":"Ann Epidemiol"},{"issue":"3","key":"2020033011375257700_B35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jhin.2008.04.030","article-title":"Validity of electronic surveillance systems: a systematic review","volume":"69","author":"Leal","year":"2008","journal-title":"J Hosp Infect"},{"issue":"8","key":"2020033011375257700_B36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.mlr.0000132391.59713.0d","article-title":"Validity of procedure codes in International Classification of Diseases, 9th revision, clinical modification administrative data","volume":"42","author":"Quan","year":"2004","journal-title":"Med Care"},{"issue":"2","key":"2020033011375257700_B37","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1017\/S0950268807008564","article-title":"ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged &gt; or = 65 years","volume":"136","author":"Skull","year":"2008","journal-title":"Epidemiol Infect"},{"issue":"9","key":"2020033011375257700_B38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jamapediatrics.2013.186","article-title":"Identifying pediatric community-acquired pneumonia hospitalizations: Accuracy of administrative billing codes","volume":"167","author":"Williams","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"1","key":"2020033011375257700_B40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1053\/j.seminhematol.2011.10.009","article-title":"Challenges to preventing infectious complications, decreasing re-hospitalizations, and reducing cost burden in long-term survivors after allogeneic hematopoietic stem cell transplantation","volume":"49","author":"Fuji","year":"2012","journal-title":"Semin Hematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1232\/1722749\/advancesadv2020001470.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/7\/1232\/1722749\/advancesadv2020001470.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T11:38:19Z","timestamp":1585568299000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/7\/1232\/454150\/Late-infectious-complications-in-hematopoietic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,30]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001470","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,30]]}}}